PRESS RELEASE
For Immediate Release:

MED –RX Supply to distribute newly FDA-approved RADIESSE cosmetic dermal filler..

January 22, 2007 – Pharma Holdings’ subsidiary Med-RX Supply has entered into a distribution sales agreement with CPI to distribute the newly FDA-approved cosmetic filler, RADIESSE.

RADIESSE, although approved worldwide for many years, has just received FDA approval in the USA as of December 27, 2006. RADIESSE is the next-generation cosmetic dermal filler for long lasting correction of moderate to severe facial wrinkles and folds. RADIESSE also received a second FDA approval for the long-lasting correction of facial fat loss (lipoatrophy) in people with HIV virus. It’s the only product of its kind to receive two separate FDA approvals in the USA. The approval of RADIESSE ushers in a new era in the non-surgical management of facial aging because it both volumizes facial folds, and rebuilds the skin’s foundation to restore a youthful facial appearance for patients.

Med-RX plans to market RADIESSE to the specialized plastic surgery market which includes surgeons, dermatologists and industry professionals throughout the world. Additionally, Med-RX plans to initiate several forms of media including direct mail, space advertising and telemarketing to sell these products worldwide. With more than 25 years experience in the direct marketing and advertising industry, Mr. Edward Klapp, CEO, Pharma Holdings has a successful track-record marketing products on a business-to-business and direct-to-consumer basis.

According to Mr. Klapp, Med-RX will begin marketing this product immediately through the CanadianDrugOutletStore.com website. Mr. Klapp expects to sell more than $100,000 in inventory per month within the first six months and plans for sales to exceed $10 million in the first year of sales on these products.

Currently, Med-RX supply will limit its sales to the Internet and Canada, but plans to expand as the business grows.